Targeting vascular endothelial growth factor (VEGF) and its receptor, VEGFR2 (KDR) may inhibit both AML cells and endothelial cell proliferation as both possess these receptors (Ziegler et al., 1999). This evidence concerns the gene KDR and acute myeloid leukemia.